Breaking News Instant updates and real-time market news.

DXCM

Dexcom

$72.35

-2.61 (-3.48%)

, ABT

Abbott

$51.69

-0.31 (-0.60%)

04:53
09/15/17
09/15
04:53
09/15/17
04:53

Dexcom initiated with an Equal Weight at Barclays

Barclays analyst Matthew Taylor started Dexcom (DXCM) with an Equal Weight rating and $76 price target. The analyst sees a "choppy" few quarters for the business and shares amid competition from Abbott (ABT) and Medtronic (MDT).

DXCM

Dexcom

$72.35

-2.61 (-3.48%)

ABT

Abbott

$51.69

-0.31 (-0.60%)

MDT

Medtronic

$81.80

-0.13 (-0.16%)

  • 19

    Sep

  • 20

    Sep

DXCM Dexcom
$72.35

-2.61 (-3.48%)

08/02/17
SPHN
08/02/17
NO CHANGE
Target $83
SPHN
Overweight
Dexcom price target lowered to $83 from $95 at Stephens
Stephens analyst Chris Cooley lowered his price target for Dexcom to $83 from $95 after the company reported Q2 operating results. The analyst reiterates an Overweight rating on the shares.
08/16/17
PIPR
08/16/17
NO CHANGE
Target $87
PIPR
Overweight
Piper calls Dexcom fears overblown, ups price target to $87
After analyzing the impact of Abbott's (ABT) FreeStyle Libre approval and Medtronic's (MDT) 670G rollout, Piper Jaffray analyst Matt O'Brien believes competitive fears for Dexcom (DXCM) are overblown. The ultimate impact on Dexcom from these technologies "will be less than feared" as FreeStlye Libre is unlikely to get a non-adjunctive claim and the 670G roll out will be slower than expected, O'Brien tells investors in a research note. He expects this to drive multiple expansion for Dexcom shares. The analyst upped his price target for the stock to $87 from $78 and keeps an Overweight rating on the name.
08/22/17
JPMS
08/22/17
NO CHANGE
JPMS
Overweight
Medtronic challenges in diabetes good news for Dexcom, Tandem, says JPMorgan
JPMorgan analyst Michael Weinstein noted that Medtronic (MDT) guided for its diabetes revenues to be down sequentially in the second and third quarters and lowered its diabetes growth guidance for the year. He said Medtronic's challenges "are naturally competitors' gains," and tells investors that he expects Dexcom (DXCM) and Tandem Diabetes (TNDM) to respond favorably to the news. Weinstein has an Overweight rating on Dexcom shares.
09/07/17
PIPR
09/07/17
NO CHANGE
PIPR
Overweight
Dexcom partnership with Fitbit has 'deeper potential,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien noted that Fitbit (FIT) and Dexcom (DXCM) have announced a collaboration that will initially allow Fitbit Iconic users to see their CGM data on their wrists, but he believes there is a "deeper potential" for the two to work together and potentially add a heart rate monitor to a future closed loop system. However, he notes he has not confirmed with either company that any such plans are in the works. O'Brien remains positive on Dexcom shares and keeps an Overweight rating on the name.
ABT Abbott
$51.69

-0.31 (-0.60%)

08/17/17
SBSH
08/17/17
INITIATION
Target $53
SBSH
Neutral
Abbott initiated with a Neutral at Citi
Citi analyst Amit Hazan started Abbott Laboratories with a Neutral rating and $53 price target. The analyst believes the company's top line growth potential is balanced out by major product and integration uncertainties following the recent acquisitions.
07/13/17
BTIG
07/13/17
NO CHANGE
BTIG
Buy
Abbott, Bigfoot deal a 'major validation' for both, says BTIG
BTIG analyst Sean Lavin sees Abbott's (ABT) deal to collaborate with Bigfoot Biomedical as a major validation of both Abbott's Libre technology and the platform of Bigfoot, which he views as a leader in the development of automated pancreases. For Dexcom (DXCM), this is a missed opportunity that could also be a sign that its grip on the CGM market may fade over time, but the company still has multiple shots with other pump systems and remains the market leader of standalone CGM, said Lavin. Insulet (PODD) is well underway in developing its Horizon AP platform and is unlikely to switch from Dexcom for its CGM, added Lavin, who keeps a Buy rating on Abbott and a Neutral rating on Dexcom.
07/14/17
COWN
07/14/17
NO CHANGE
Target $55
COWN
Outperform
Abbott likely biggest beneficiary of CMS changes for MRI coverages, says Cowen
Cowen analyst Joshua Jennings said he believes the CMS will consider covering MRI for patients with CRM devices that do not have FDA-approved MR-safe labeling. Jennings believes this should neutralize any unanticipated fallout from Abbott's Sylmar facility warning letter if it removes the need to secure MR-safe labeling. The analyst, who said he hopes to gain insight into the MRI considerations over the next month, maintained his Outperform rating and $55 price target on Abbott shares.
MDT Medtronic
$81.80

-0.13 (-0.16%)

08/22/17
COWN
08/22/17
NO CHANGE
Target $95
COWN
Outperform
Medtronic positioned to bounce off of Q1 slowdown, says Cowen
Cowen analyst Joshua Jennings noted Medtronic's recent top-line momentum was thwarted by an IT problem and capacity constraint in Diabetes, but he believes organic revenue growth should rebound to the roughly 4% range. He cited soft comps and a tailwind from the Supplies divestiture. Jennings reiterated his Outperform rating and $95 price target on Medtronic shares.
08/28/17
08/28/17
DOWNGRADE

Underperform
NuVasive downgraded to Underperform at Needham
As previously reported, Needham analyst Mike Matson downgraded NuVasive (NUVA) to Underperform from Hold saying that his math indicates that consensus revenue estimates require an acceleration in its market share gains but NuVasive's rate of market share gain is more likely to decrease given the improving spine performance at Medtronic (MDT). Further, the analyst believes that slower revenue growth is likely to limit operating leverage putting consensus EPS estimates at risk as well. Matson expects NuVasive's revenue growth to approach the mid-single digits and its EPS growth to approach the mid-teens.
09/11/17
SBSH
09/11/17
NO CHANGE
Target $97
SBSH
Buy
Citi removes Medtronic as best idea for 2017 in Medical Supplies
Citi analyst Amit Hazan removed Medtronic (MDT) as his best idea for 2017 in Medical Supplies & Technology. His best idea is now Sell-rated Edwards Lifesciences (EW). After analyzing his thesis, Hazan is more cautious on Medtronic's sales growth relative to guidance for the year. The analyst highlights management's "consistent" execution challenges and communication problems. He cut his price target for Medtronic to $97 from $104 and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

ICPT

Intercept

$96.20

0.45 (0.47%)

05:01
09/20/17
09/20
05:01
09/20/17
05:01
Recommendations
Intercept analyst commentary  »

Intercept recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

04:57
09/20/17
09/20
04:57
09/20/17
04:57
Downgrade
Yahoo Japan rating change  »

Yahoo Japan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$19.25

1.4 (7.84%)

04:56
09/20/17
09/20
04:56
09/20/17
04:56
Initiation
Epizyme initiated  »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

CSGP

CoStar Group

$280.60

3.97 (1.44%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
CoStar Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

YEXT

Yext

$12.99

-0.27 (-2.04%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Yext management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FCFS

First Cash Financial

$60.65

0.65 (1.08%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
First Cash Financial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

VNRX

VolitionRx

$2.75

0.07 (2.61%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
VolitionRx management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Citigroup to hold a conference »

2017 SMID and Travel…

SRCL

Stericycle

$70.19

-0.81 (-1.14%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Stericycle management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 27

    Sep

FIVN

Five9

$22.17

0.31 (1.42%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Five9 management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

GMS

GMS Inc.

$33.50

-0.38 (-1.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
GMS Inc. management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

HRTG

Heritage Insurance

$11.83

-0.72 (-5.74%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Heritage Insurance management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

HZNP

Horizon Pharma

$12.10

0.26 (2.20%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Horizon Pharma management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Omega Healthcare management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MZDAF

Mazda

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Mazda management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

SFS

Smart & Final Stores

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Smart & Final Stores management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SRCI

SRC Energy

$8.18

0.16 (2.00%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
SRC Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 16

    May

EMR

Emerson

$63.21

0.22 (0.35%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Emerson management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
General news
Existing Home Sales to be reported at 10:00 »

August Existing Home…

SCSC

Scansource

$40.70

-0.05 (-0.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Scansource management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

ARLP

Alliance Resource Partners

$18.90

-0.05 (-0.26%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Alliance Resource Partners management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Piper Jaffray to hold a tour »

Permian Basin BBQ &…

AITB

AIT Therapeutics

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
AIT Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

BRG

Bluerock Residential

$10.48

0.06 (0.58%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Oct

DAIO

Data I/O

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Data I/O management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.